CERS Logo

Cerus Corporation (CERS) 

NASDAQ
Market Cap
$293.43M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
326 of 960
Rank in Industry
39 of 120

Largest Insider Buys in Sector

CERS Stock Price History Chart

CERS Stock Performance

About Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood …

Insider Activity of Cerus Corporation

Over the last 12 months, insiders at Cerus Corporation have bought $51,042 and sold $1.09M worth of Cerus Corporation stock.

On average, over the past 5 years, insiders at Cerus Corporation have bought $215,060 and sold $3.59M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Witney Frank (director) — $37,800. Swisher Daniel N JR (director) — $14,066. NACHTSHEIM JAMI K (director) — $7,156.

The last purchase of 2,500 shares for transaction amount of $4,975 was made by Shan Hua (director) on 2024‑05‑13.

List of Insider Buy and Sell Transactions, Cerus Corporation

2024-12-16SaleChief Legal Officer
16,667
0.0086%
$1.71$28,501-9.17%
2024-12-12Saledirector
20,000
0.0108%
$1.78$35,700-4.49%
2024-09-04SaleChief Financial Officer
54,272
0.0299%
$2.15$116,826-15.64%
2024-09-03SaleChief Financial Officer
28,385
0.0153%
$2.18$61,919-18.72%
2024-08-15SaleChief Legal Officer
16,667
0.0092%
$2.06$34,4170.00%
2024-08-02SaleChief Medical Officer
21,605
0.0125%
$2.50$54,013-22.98%
2024-05-13Purchasedirector
2,500
0.0013%
$1.99$4,975-9.00%
2024-05-10Purchasedirector
2,000
0.0011%
$1.79$3,578+5.20%
2024-05-09Purchasedirector
20,000
0.0107%
$1.89$37,800-5.21%
2024-05-09Purchasedirector
2,500
0.0013%
$1.88$4,689-5.21%
2024-03-14SalePresident and CEO
63,611
0.0349%
$2.02$128,195-9.05%
2024-03-14SaleChief Scientific Officer
14,360
0.0077%
$1.97$28,352-9.05%
2024-03-14SaleChief Operating Officer
26,794
0.0144%
$1.97$52,902-9.05%
2024-03-14SaleChief Financial Officer
21,497
0.0116%
$1.97$42,444-9.05%
2024-03-14SaleChief Legal Officer
17,824
0.0096%
$1.97$35,192-9.05%
2024-03-14SaleChief Medical Officer
17,738
0.0095%
$1.97$35,022-9.05%
2024-03-13SalePresident and CEO
62,315
0.0349%
$2.06$128,182-10.40%
2024-03-13SaleChief Scientific Officer
14,067
0.0079%
$2.06$28,936-10.40%
2024-03-13SaleChief Operating Officer
26,247
0.0147%
$2.06$53,990-10.40%
2024-03-13SaleChief Financial Officer
21,058
0.0116%
$2.02$42,438-10.40%

Insider Historical Profitability

23.06%
Greenman William MarinerPresident and CEO
3181281
1.713%
$1.58512+31.07%
CORASH LAURENCE MChief Scientific Officer
2339740
1.2599%
$1.58378+15.14%
Witney Frankdirector
180059
0.097%
$1.5820+47.63%
BJERKHOLT ERICdirector
162133
0.0873%
$1.5841+22.01%
NACHTSHEIM JAMI Kdirector
108362
0.0583%
$1.5820+47.63%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
ARK Investment Management LLC$40.72M11.6521.55M+3.02%+$1.19M0.14
Baker Bros Advisors LP$36.81M10.5419.48M0%+$00.26
BlackRock$25.77M7.3813.64M-0.67%-$172,825.38<0.01
The Vanguard Group$18.87M5.49.98M+1.15%+$214,121.88<0.0001
PRIMECAP Management Co$16.22M4.648.58M-0.34%-$54,810.000.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.